This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Leland Stanford Junior University. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Aimee Shen: Innovator in Clostridium Difficile Treatment
Introduction
Aimee Shen is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of medical research, particularly in the treatment of infections caused by Clostridium difficile. Her innovative work has led to the development of novel therapeutic methods aimed at reducing the toxicity associated with this infection.
Latest Patents
Aimee Shen holds a patent for the "Use of small molecules for the treatment of clostridium difficile toxicity." This patent discloses methods and compositions for reducing toxicity associated with infection by inhibiting toxin B (TcdB) and/or toxin A (TcdA). The compounds include ebselen compounds, such as ebselen and its salts, ebselen functional analogues, and ebselen structural analogues, along with certain amide derivatives. The patent also details specific formulas, including Formula I, e.g., 1-methyl-3-phenylpropylamine; Formula II, e.g., 2,2'-diselane-1,2-diylbis[N-(2,4-difluorophenyl)benzamide]; and Formula III, e.g., 2-(2-methoxy-5-methylphenyl)-1,2-benzoselenazol-3-one. The present compositions may be comprised in a colon-retentive formulation that increases the residence of and/or release of the compound in the area where the infection is active.
Career Highlights
Aimee Shen is affiliated with Leland Stanford Junior University, where she continues her research and development efforts. Her work has garnered attention for its potential impact on public health, particularly in combating antibiotic-resistant infections.
Collaborations
Aimee has collaborated with notable colleagues, including Aaron Puri and Kristina Oresic Bender. These partnerships have further enhanced her research capabilities and broadened the scope of her innovative projects.
Conclusion
Aimee Shen is a trailblazer in the field of medical innovation, particularly in the treatment of Clostridium difficile infections. Her patent and ongoing research efforts reflect her commitment to improving health outcomes through scientific advancements.